Key Metrics
CiteScore 

3
Recommended pre-submission checks
Powered by 

Immuno-Oncology and Technology Journal Specifications
Indexed in the following public directories
Scopus
DOAJ
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | EUR 2750 |
| Publication Time | 29 |
| Editorial Review Process | Double blind peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Society for Medical Oncology |
| Website URL | Visit website |
| Publication Details | |
| Publication Time | 29 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Immuno-Oncology and Technology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Immuno-Oncology and Technology
Why CD4+ T cells matter in adoptive cell therapy for solid cancers.
- 1 Dec 2026
- Immuno-oncology technology
Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients.
- 1 Dec 2026
- Immuno-oncology technology
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
- 17 Sep 2026
- Immuno-Oncology and Technology
Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma
- 17 Sep 2026
- Immuno-Oncology and Technology
Editorial Board
- 1 Sep 2026
- Immuno-Oncology and Technology
Table of Contents
- 1 Sep 2026
- Immuno-Oncology and Technology
Why CD4+ T cells matter in adoptive cell therapy for solid cancers.
- 1 Dec 2026
- Immuno-oncology technology
Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients.
- 1 Dec 2026
- Immuno-oncology technology
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
- 17 Sep 2026
- Immuno-Oncology and Technology
Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma
- 17 Sep 2026
- Immuno-Oncology and Technology
Editorial Board
- 1 Sep 2026
- Immuno-Oncology and Technology
Table of Contents
- 1 Sep 2026
- Immuno-Oncology and Technology